The PLCRC substudy Ultra high field 7.0 Tesla MR Spectroscopy to monitor capecitabine metabolism in liver metastases - a proof of concept study - The PLCRC - SPECTRE study

niversitair Medisch Centrum Utrecht0 个研究点目标入组 26 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•-18 years or older.
•-Patients with liver metastases measurable according to RECIST in metastatic colorectal cancer.
•-Patients that are planned to start with capecitabine and bevacizumab treatment as determined according to Dutch guidelines.
•-Informed consent for longitudinal data collection according to the PLCRC study protocol.

•Patients receiving triple chemotherapy for mCRC.
•Patients that received or currently receive any other kind of systemic therapy for cancer.
•Patients that received any prior radiotherapy or surgery in the liver.
•Patients with a dihydropyrimindine dehydrogenase (DPD) deficiency (heterozygous or homozygous).
•Contra-indications to MRI scanning according to hospitals 7T MRI screening guideline of the UMCU.
•Patients with severe liver dysfunction.
•Patients with a life expectancy of < 3 months.
•Pregnant or lactating women.
•Claustrofobia.
•Exclusion criteria phase 2
•Patients that withdraw treatment with capecitabine and bevacizumab within the first three cycli.

发起方

niversitair Medisch Centrum Utrecht